Literature DB >> 22158568

Denosumab for the treatment of osteoporosis and cancer-related conditions.

E M Lewiecki1, J P Bilezikian.   

Abstract

Osteoporotic fractures and adverse skeletal effects of malignancies are associated with high bone turnover. Denosumab is a potent inhibitor of bone resorption with a novel mechanism of action. It is administered as an infrequent subcutaneous injection with no restrictions relating to renal function. This review summarizes data on the efficacy and safety of denosumab that led to its approval for the treatment of postmenopausal osteoporosis, cancer treatment-induced bone loss, and skeletal complications of malignancies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22158568     DOI： 10.1038/clpt.2011.268

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism.

Authors:  Christian Santa Maria; Zhiqiang Cheng; Alfred Li; Jiali Wang; Dolores Shoback; Chia-Ling Tu; Wenhan Chang
Journal:  Semin Cell Dev Biol       Date:  2015-12-10       Impact factor: 7.727

2.  Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.

Authors:  Mohamed A Yassin; Ashraf T Soliman; Vincenzo De Sanctis; Mohamed Osman Abdelrahman; Elsaid M Aziz Bedair; Manal AbdelGawad
Journal:  Indian J Endocrinol Metab       Date:  2014-07

3.  BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Authors:  Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Oncotarget       Date:  2017-05-23

Review 4.  A Review on the Role of Denosumab in Fracture Prevention.

Authors:  Kok-Lun Pang; Nie Yen Low; Kok-Yong Chin
Journal:  Drug Des Devel Ther       Date:  2020-10-01       Impact factor: 4.162

5.  Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.

Authors:  Tarun Kadaru; Amal Shibli-Rahhal
Journal:  J Bone Metab       Date:  2021-02-28

Review 6.  Management of bone metastases in refractory prostate cancer--role of denosumab.

Authors:  Channing J Paller; Michael A Carducci; George K Philips
Journal:  Clin Interv Aging       Date:  2012-09-17       Impact factor: 4.458

7.  Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow.

Authors:  Shinichiro Kuroshima; Zeina Al-Salihi; Junro Yamashita
Journal:  Clin Oral Investig       Date:  2015-08-09       Impact factor: 3.573
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.